Drug Profile
Research programme: arrhythmias therapeutics - Pierre Fabre
Alternative Names: 16915; F 16915Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arrhythmias in France
- 31 Dec 2007 Preclinical trials in Arrhythmias in France (unspecified route)